Two people infected with the same strain of COVID-19 can have vastly different experiences. One might never even sniffle, and ...

CAR-T cell therapy has revolutionized the treatment landscape for specific blood cancers, yet access to this innovative ...

Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support ...

Artificial intelligence has now moved from predicting the shapes of proteins to designing the molecular sensors of the human ...

An international multidisciplinary group of 31 experts has updated consensus recommendations to guide the use of CAR T-cell ...

Caribou Biosciences is discontinuing its two allogeneic CAR-T programs and exploring strategic alternatives to maximize shareholder value. Caribou Biosciences, Inc. announced that it is exploring ...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...

Vir Biotechnology has exclusive rights to the universal PRO-XTEN ® masking platform for oncology and infectious disease. PRO-XTEN ® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.

New office and laboratory at CIC Philadelphia will support US biopharma companies, CDMOs, and research institutions ...

An international panel of 31 experts has published updated 2026 consensus recommendations in The Lancet Rheumatology guiding ...

Abogen Biosciences has entered into a licensing and option agreement with Novartis covering ABO2203 and additional potential ...

Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager . Agreement also gives Novartis ...